INTELLIA THERAPEUTICS, INC. (NTLA) Overview
- 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual -0.80; Beat / miss (m).
- 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -0.81; Beat / miss (m).
- 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual -0.92; Beat / miss (m).
- 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -0.98; Beat / miss (m).
Stock Price Chart
View more →Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
- Last close
- $11.34
- Previous close
- $12.03
- Change
- -$0.69
- Change (%)
- -5.74%
- Close date
- 2026-11-06
- Previous close date
- 2026-09-29
- Open
- (m)
- Day high
- (m)
- Day low
- (m)
- Last session volume
- (m)
- Last session value
- (m)
- Currency
- USD
- Price basis
- split-adjusted
- Volume basis
- (m)
Performance
View more →Cumulative total returns · 2026-09-29
YTD
- NTLA
- +33.82%
- S&P 500
- (m)
1 year
- NTLA
- -28.90%
- S&P 500
- (m)
3 years
- NTLA
- -61.95%
- S&P 500
- (m)
5 years
- NTLA
- -91.25%
- S&P 500
- (m)
Earnings trends
View more →Earnings per share
USD / share · As filed
30 Jun 2026 ○ Estimate (m) ● Actual -0.80
Comparison details
| Period start | Period ending | Estimate | Actual | Beat / miss | Report date |
|---|---|---|---|---|---|
| 1 Apr 2026 | 30 Jun 2026 | (m) | -0.80 | (m) | (m) |
| 1 Jan 2026 | 31 Mar 2026 | (m) | -0.81 | (m) | (m) |
| 1 Jul 2025 | 30 Sept 2025 | (m) | -0.92 | (m) | (m) |
| 1 Apr 2025 | 30 Jun 2025 | (m) | -0.98 | (m) | (m) |
| 1 Jan 2025 | 31 Mar 2025 | (m) | -1.10 | (m) | (m) |
31 Dec 2025 ○ Estimate (m) ● Actual -3.81
Comparison details
| Period start | Period ending | Estimate | Actual | Beat / miss | Report date |
|---|---|---|---|---|---|
| 1 Jan 2025 | 31 Dec 2025 | (m) | -3.81 | (m) | (m) |
| 1 Jan 2024 | 31 Dec 2024 | (m) | -5.25 | (m) | (m) |
| 1 Jan 2023 | 31 Dec 2023 | (m) | -5.42 | (m) | (m) |
| 1 Jan 2022 | 31 Dec 2022 | (m) | -6.16 | (m) | (m) |
| 1 Jan 2021 | 31 Dec 2021 | (m) | -3.78 | (m) | (m) |
(m)
Revenue vs. Earnings
USD
30 Jun 2026 ■ Revenue 7.66M ■ Earnings -106.63M — Profit margin -1392.27%
31 Dec 2025 ■ Revenue 67.67M ■ Earnings -412.69M — Profit margin -609.85%
Analyst insights
View more →| Ratings | Buy | Hold | Sell | Other ratings | Last Close | Average Target | Upside | High Target | Low Target |
|---|---|---|---|---|---|---|---|---|---|
| (m) | (m) | (m) | (m) | (m) | $11.34 | (m) | (m) | (m) | (m) |
Recent news
View more →(m)
YouTube videos mentioning NTLA
View more →(m)
Statistics
View more →Retained observations as of 2026-11-11; financial period ending 30 Jun 2026.
- Forward P/E
- (m)
- PEG ratio · 5-year expected
- (m)
- Shares held by insiders
- (m)
- Insider transactions · change (%)
- (m)
- Shares held by institutions
- (m)
- Institutional transactions · change (%)
- (m)
- Diluted EPS · 12 month
- (m)
- EPS estimate · next quarter
- (m)
- EPS estimate · next year
- (m)
- EPS growth · current annual estimate
- (m)
- EPS growth · next annual estimate
- (m)
- EPS growth · next 5 years expected
- (m)
- EPS growth · past 3 years annualized
- (m)
- EPS growth · past 5 years annualized
- (m)
- EPS change · 12 months vs prior year
- (m)
- EPS change · latest quarter vs previous quarter
- (m)
- Latest earnings report date
- (m)
- EPS surprise · latest reported quarter
- (m)
- Net income · 12 month
- $-399.98M
- Operating margin · 12 months
- -711.66%
- Profit margin
- -672.16%
- Return on assets · 12 month
- -45.55%
- Index membership
- (m)
- Employees
- 377.00
- IPO date
- (m)
- Options available
- (m)
- Shortable
- (m)
- Analyst recommendation
- (m)
- Analyst target price
- (m)
- Price volatility · week
- (m)
- Price volatility · month
- (m)
- Average true range · 14 sessions
- (m)
- Relative strength index · 14 sessions
- (m)
- Relative volume
- (m)
- Average daily volume
- 4.06M
- Latest session volume
- (m)
- Last session value
- (m)
- 30 days ago session value
- (m)
- 1 year ago session value
- (m)
- Number of trades
- (m)
- Total return · week
- -5.20%*
- Total return · month
- -6.53%*
- Total return · quarter
- -27.57%*
- Total return · half year
- -2.75%*
- Total return · year to date
- 33.82%*
- Total return · 1 year
- -28.90%*
- Total return · 3 years
- -61.95%*
- Total return · 5 years
- -91.25%*
- Market cap
- (m)
- Book value per share · latest quarter
- (m)
- Price / cash · latest quarter
- (m)
- Enterprise value
- (m)
- Enterprise value / revenue
- (m)
- Enterprise value / EBITDA
- (m)
- Dividend · 12 months per share
- (m)
- Dividend ex-date
- (m)
- Next dividend ex-date
- (m)
- Next dividend amount per share
- (m)
- Dividend growth · 3 years annualized
- (m)
- Dividend growth · 5 years annualized
- (m)
- R&D / revenue · 12 months
- 582.68%
- Revenue · 12 month
- $59.51M
- Revenue growth · past 3 years annualized
- (m)
- Revenue growth · past 5 years annualized
- (m)
- Revenue change · 12 months vs prior year
- (m)
- Revenue change · latest quarter vs previous quarter
- (m)
- Revenue surprise · latest reported quarter
- (m)
- Operating cash flow · 12 months
- $-346.64M
- Free cash flow · 12 months (USD)
- $-348.69M
- Levered free cash flow · 12 month
- (m)
- Debt / equity · latest quarter
- (m)
- Long-term debt / equity · latest quarter
- (m)
- Return on equity · 12 month
- (m)
- Return on invested capital · 12 months
- (m)
- Previous close
- (m)
- Latest closing price
- (m)
- Latest session change (%)
- (m)
- 52-week high
- (m)
- 52-week low
- (m)
- Price vs 20-session moving average
- (m)
- Price vs 50-session moving average
- (m)
- Price vs 200-session moving average
- (m)
- Float shares
- (m)
- Short float (%)
- (m)
- Short ratio (days to cover)
- (m)
- Short interest (shares)
- (m)
Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.
Holders breakdown
View more →| Breakdown | Ownership |
|---|---|
| (m) | Shares held by all insiders |
| (m) | Shares held by institutions |
| (m) | Float held by institutions |
| (m) | Institutions holding shares |
Other holders
(m)
Insider holders
(m)
Top institutional holders
(m)
Top mutual fund holders
(m)
INTELLIA THERAPEUTICS, INC. Overview
View more →(m)
(m)
- SEC CIK
- 1652130
- Industry (SIC)
- 2835 In Vitro & In Vivo Diagnostic Substances
- Country of operation
- United States
- Business address
- 40 ERIE STREET, SUITE 130, CAMBRIDGE, Massachusetts, 02139, United States
- Fiscal year end
- 1231
- Phone
- 857-285-6200
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |